HC Wainwright Has Bearish Outlook for AGIO FY2028 Earnings

Agios Pharmaceuticals, Inc. (NASDAQ:AGIO) – Equities researchers at HC Wainwright decreased their FY2028 earnings per share estimates for shares of Agios Pharmaceuticals in a report released on Monday, July 13th. HC Wainwright analyst E. Bodnar now expects that the biopharmaceutical company will earn ($4.69) per share for the year, down from their previous forecast of ($4.65). HC Wainwright currently has a “Buy” rating and a $50.00 target price on the stock. The consensus estimate for Agios Pharmaceuticals’ current full-year earnings is ($6.32) per share. HC Wainwright also issued estimates for Agios Pharmaceuticals’ FY2029 earnings at ($3.11) EPS and FY2030 earnings at ($0.25) EPS.

Several other research firms have also recently issued reports on AGIO. Bank of America lifted their price objective on Agios Pharmaceuticals from $40.00 to $46.00 and gave the stock a “buy” rating in a report on Tuesday, July 7th. JPMorgan Chase & Co. decreased their target price on Agios Pharmaceuticals from $36.00 to $31.00 and set a “neutral” rating on the stock in a research report on Thursday, June 11th. The Goldman Sachs Group raised their target price on Agios Pharmaceuticals from $28.00 to $32.00 and gave the company a “neutral” rating in a research report on Wednesday, April 1st. Royal Bank Of Canada lifted their price target on Agios Pharmaceuticals from $28.00 to $32.00 and gave the stock a “sector perform” rating in a research note on Tuesday, July 7th. Finally, Weiss Ratings reiterated a “sell (d)” rating on shares of Agios Pharmaceuticals in a research report on Wednesday, June 24th. Six analysts have rated the stock with a Buy rating, four have given a Hold rating and one has assigned a Sell rating to the stock. According to MarketBeat, Agios Pharmaceuticals currently has an average rating of “Hold” and an average price target of $42.56.

Agios Pharmaceuticals Stock Down 1.6%

AGIO opened at $39.92 on Wednesday. The company has a market cap of $2.37 billion, a PE ratio of -5.51 and a beta of 0.54. Agios Pharmaceuticals has a twelve month low of $22.24 and a twelve month high of $46.00. The company has a 50-day moving average price of $32.30 and a 200 day moving average price of $30.10.

Agios Pharmaceuticals (NASDAQ:AGIO) last announced its earnings results on Wednesday, April 29th. The biopharmaceutical company reported ($1.69) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($1.81) by $0.12. Agios Pharmaceuticals had a negative return on equity of 34.11% and a negative net margin of 639.84%.The firm had revenue of $20.75 million for the quarter, compared to analyst estimates of $13.30 million. The company’s revenue for the quarter was up 137.7% compared to the same quarter last year.

Institutional Investors Weigh In On Agios Pharmaceuticals

Several hedge funds and other institutional investors have recently made changes to their positions in the stock. SG Americas Securities LLC raised its position in shares of Agios Pharmaceuticals by 68.0% during the 4th quarter. SG Americas Securities LLC now owns 46,451 shares of the biopharmaceutical company’s stock valued at $1,264,000 after buying an additional 18,801 shares during the period. Assenagon Asset Management S.A. lifted its holdings in Agios Pharmaceuticals by 64.5% in the fourth quarter. Assenagon Asset Management S.A. now owns 110,440 shares of the biopharmaceutical company’s stock valued at $3,006,000 after acquiring an additional 43,287 shares during the last quarter. GW&K Investment Management LLC grew its position in Agios Pharmaceuticals by 41.5% in the fourth quarter. GW&K Investment Management LLC now owns 1,207,301 shares of the biopharmaceutical company’s stock worth $32,863,000 after acquiring an additional 354,359 shares during the period. State of New Jersey Common Pension Fund D purchased a new position in Agios Pharmaceuticals in the fourth quarter worth approximately $1,291,000. Finally, Erste Asset Management GmbH increased its stake in Agios Pharmaceuticals by 1.4% during the fourth quarter. Erste Asset Management GmbH now owns 2,804,900 shares of the biopharmaceutical company’s stock worth $76,343,000 after acquiring an additional 40,000 shares during the last quarter.

Agios Pharmaceuticals Company Profile

Agios Pharmaceuticals, Inc is a biopharmaceutical company founded in 2008 as a spin-out from research at Dana-Farber Cancer Institute and the Broad Institute. Headquartered in Cambridge, Massachusetts, Agios focuses on understanding and targeting cellular metabolism to develop novel therapies for cancer and rare genetic diseases. The company’s scientific platform integrates genomic discovery, metabolic profiling and precision medicine approaches to identify and advance small-molecule candidates that correct or exploit metabolic dysfunction.

Agios’s lead products are IDH (isocitrate dehydrogenase) inhibitors that target specific cancer mutations.